Stephen Silvestro Sells 1,620 Shares of OptimizeRx (NASDAQ:OPRX) Stock

Key Points

• CEO Stephen Silvestro sold 1,620 shares of OptimizeRx stock for a total value of $30,375, reducing his ownership by 0.85%.
• OptimizeRx's stock price increased by 1.5% to $17.95, with a year high at $20.69 and a market capitalization of $333.24 million.
• Analyst ratings for OptimizeRx have varied, with JMP Securities raising their price target from $14.00 to $20.00 and Zacks Research upgrading the stock to a "strong buy" rating.

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) CEO Stephen Silvestro sold 1,620 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $18.75, for a total value of $30,375.00. Following the completion of the sale, the chief executive officer owned 188,916 shares in the company, valued at approximately $3,542,175. The trade was a 0.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

OptimizeRx Stock Up 1.5%

NASDAQ:OPRX traded up $0.27 during mid-day trading on Tuesday, hitting $17.95. The stock had a trading volume of 281,221 shares, compared to its average volume of 380,940. The stock has a 50-day simple moving average of $17.02 and a two-hundred day simple moving average of $13.29. The company has a market capitalization of $333.24 million, a PE ratio of -33.24 and a beta of 1.25. OptimizeRx Corp. has a twelve month low of $3.78 and a twelve month high of $20.69. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.21.

Analyst Ratings Changes

Several brokerages have commented on OPRX. JMP Securities increased their price target on shares of OptimizeRx from $14.00 to $20.00 and gave the company a "market outperform" rating in a research note on Monday, August 11th. Zacks Research raised OptimizeRx from a "hold" rating to a "strong-buy" rating in a report on Friday, September 5th. Roth Capital reissued a "buy" rating on shares of OptimizeRx in a research report on Friday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of OptimizeRx in a research report on Saturday, September 27th. Finally, Stifel Nicolaus boosted their price objective on OptimizeRx from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $11.81.

Institutional Investors Weigh In On OptimizeRx

A number of large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its position in OptimizeRx by 600.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company's stock worth $29,000 after purchasing an additional 1,818 shares in the last quarter. GAMMA Investing LLC acquired a new stake in shares of OptimizeRx during the 1st quarter worth about $33,000. Quantbot Technologies LP purchased a new position in shares of OptimizeRx during the second quarter valued at approximately $44,000. BNP Paribas Financial Markets boosted its position in OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company's stock worth $55,000 after acquiring an additional 2,215 shares during the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in OptimizeRx in the 1st quarter worth approximately $99,000. Institutional investors and hedge funds own 76.47% of the company's stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.